Unlocking the full potential of inhalation technologies and therapies

Senzer develops, manufactures and licences breakthrough respiratory products for the effective delivery of pharmaceutical cannabinoids

Unique respiratory cannabinoid delivery

Senzer is a pharmaceutical company which develops, manufactures and licences innovative respiratory devices for the safe and reliable delivery of pharmaceutical cannabinoids – systemic therapies that deliver acute, breakthrough and refractory treatment.

Cannabinoids have long been identified as promising treatment options for a range of conditions, including those associated with cancer treatment; however, the drawbacks of oral delivery have limited their uptake. Senzer’s breakthrough inhalation platform delivers cannabinoids with a fast onset of action and high bioavailability, providing a new safe and effective treatment option that can be easily self-administered. Our products can make a real and tangible difference to a patients quality of life by advancing the treatment options available.

At Senzer, we’re discovering new ways to make life better. From research and development through to commercialisation, we explore, innovate and modify our technologies to complement and enhance existing conventional and alternative treatments to ensure we are a leader in this field.

Recent News

Sep 25 2018
Senzer Limited - Logo
Senzer Logo
Senzer Limited
Press release

New Trial Data: Senzer’s Inhaler delivers cannabinoids faster at lower doses

The physical uptake of pharmaceutical cannabinoids when inhaled through Senzer’s unique respiratory device is more than 50 times faster than oral delivery, at just a fraction of the dose, according to data released today under a clinical trial conducted in the US. Senzer, a UK-based drug delivery company, reported the success of a 36-subject pharmacokinetic...

Read More
Jul 5 2018
Senzer Limited - Logo
Senzer Logo
Senzer Limited
Press release

Senzer plans to launch its first inhaled cannabinoid products in the UK

Senzer Ltd has announced that it intends to launch its inhaled cannabinoid portfolio of products later this year in the UK under a specials pharmaceutical licence. This would enable doctors to prescribe its inhaled cannabinoid products to cancer patients undergoing chemotherapy. “Our delivery technology is a first of its kind – a respiratory delivery system...

Read More
Jul 5 2018
Senzer Limited - Logo
Senzer Logo
Senzer Limited
Press release

FDA accepts Clinical Research Plan to explore Senzer’s Inhaler for Cancer Patients

LONDON, UK – The US Food and Drug Administration have accepted an application for a clinical development study on Dronabinol Inhalation using Senzer’s unique breath-actuated inhaler, progressing the Company’s US partner, INSYS Therapeutics, on its path for approval of the device as an innovative approach to help cancer patients, Senzer said (today).

Read More